CIViC Compass
Research use only — not FDA-cleared, not medical advice. Always consult FDA-approved labeling and a qualified clinician.

CIViC Evidence Items

4766 evidence items indexed

Evidence Level Distribution

CIViC evidence levels reflect study design quality, from A (strongest) to E (weakest).

AValidated — meta-analysis, systematic review, or major guideline
BClinical — prospective trial or retrospective cohort study
CCase study — single case report or small case series
DPreclinical — in vitro or animal model data
EInferential — computational prediction or biological rationale

Gene × Evidence Type

Count of CIViC evidence items per gene and evidence type category. Hover a column header for the type definition.

PredictiveDiagnosticPrognosticFunctionalPredispos.Oncogenic
BCR::ABL132311
BRAF18642621
EGFR2481232
EML4::ALK64
ERBB21422
FLT355221
KIT10237
KRAS1594244
PIK3CA156164
PTEN5313121
TP5352401002
VHL52363515
Predictive:Links a variant to treatment response or resistance
Diagnostic:Supports or refutes a specific disease diagnosis
Prognostic:Informs disease progression or clinical outcome
Functional:Characterises the biological effect of a variant
Predisposing:Germline variant associated with cancer predisposition
Oncogenic:Characterises the variant's role in oncogenesis
LevelGeneVariantTypeDirectionSignificanceDiseaseDrugsSource
CVHLExon 3 DeletionPredisposingSupportsPredispositionVon Hippel-Lindau DiseaseWu et al., 2012
CVHLR161= (c.481C>A)PredisposingSupportsPredispositionVon Hippel-Lindau DiseaseWu et al., 2012
CVHLR167W (c.499C>T)PredisposingSupportsPredispositionVon Hippel-Lindau DiseaseWu et al., 2012
CVHLE94* (c.280G>T)PredisposingSupportsPredispositionVon Hippel-Lindau DiseaseWu et al., 2012
CVHLH115R (c.344A>G)PredisposingSupportsPredispositionVon Hippel-Lindau DiseaseWu et al., 2012
CVHLI151F (c.451A>T)PredisposingSupportsPredispositionVon Hippel-Lindau DiseaseWu et al., 2012
CVHLL178R (c.533T>G)PredisposingSupportsPredispositionVon Hippel-Lindau DiseaseWu et al., 2012
CVHLP86S (c.256C>T)PredisposingSupportsPredispositionVon Hippel-Lindau DiseaseWu et al., 2012
CVHL3'UTR alteration (c.*70C>A)PredisposingSupportsPredispositionVon Hippel-Lindau DiseaseWu et al., 2012
CVHLE70K (c.208G>A)PredisposingSupportsPredispositionVon Hippel-Lindau DiseasePark et al., 2015
CVHLQ145* (c.433C>T)PredisposingSupportsPredispositionVon Hippel-Lindau DiseaseSidhu et al., 2015
CVHLN150S (c.449A>G)PredisposingSupportsPredispositionVon Hippel-Lindau DiseaseSidhu et al., 2015
CVHLV84L (c.250G>T)PredisposingSupportsPredispositionVon Hippel-Lindau DiseaseHuff et al., 2014
CVHLY98H (c.292T>C)PredisposingSupportsPredispositionVon Hippel-Lindau DiseaseLuchetti et al., 2015
CVHLSplice Site (c.464-2A>G)PredisposingSupportsUncertain SignificanceVon Hippel-Lindau DiseaseGlavac et al., 1996
CVHLR177ins (c.531insCTGAGAGTAAAGCCTGAA)PredisposingN/AVon Hippel-Lindau DiseaseOlschwang et al., 1998
CDICER1D1709EPredisposingSupportsPredispositionSertoli-Leydig Cell TumorHeravi-Moussavi et al., 2012
BPTENLossPredictiveDoes Not SupportSensitivity/ResponseSolid TumorPaclitaxel,Buparlisib,CarboplatinSmyth et al., 2017
CBRAFV600EPredictiveSupportsSensitivity/ResponseColorectal CancerVemurafenibHainsworth et al., 2018
CBRAFG464VPredictiveDoes Not SupportSensitivity/ResponseCancerVemurafenibHainsworth et al., 2018
CBRAFG469APredictiveDoes Not SupportSensitivity/ResponseCancerVemurafenibHainsworth et al., 2018
CBRAFG496APredictiveDoes Not SupportSensitivity/ResponseCancerVemurafenibHainsworth et al., 2018
CBRAFN581SPredictiveDoes Not SupportSensitivity/ResponseCancerVemurafenibHainsworth et al., 2018
CBRAFG466VPredictiveDoes Not SupportSensitivity/ResponseCancerVemurafenibHainsworth et al., 2018
CBRAFG596RPredictiveDoes Not SupportSensitivity/ResponseCancerVemurafenibHainsworth et al., 2018
CBRAFG606EPredictiveDoes Not SupportSensitivity/ResponseCancerVemurafenibHainsworth et al., 2018
CBRAFL597QPredictiveDoes Not SupportSensitivity/ResponseCancerVemurafenibHainsworth et al., 2018
CBRAFP731TPredictiveDoes Not SupportSensitivity/ResponseCancerVemurafenibHainsworth et al., 2018
CBRAFintron 9 rearrangementPredictiveDoes Not SupportSensitivity/ResponseCancerVemurafenibHainsworth et al., 2018
CBRAFintron 10 rearrangementPredictiveDoes Not SupportSensitivity/ResponseCancerVemurafenibHainsworth et al., 2018
CMACF1::BRAFFusionPredictiveDoes Not SupportSensitivity/ResponseCancerVemurafenibHainsworth et al., 2018
CCUX1::BRAFFusionPredictiveSupportsSensitivity/ResponsePancreatic CancerVemurafenibHainsworth et al., 2018
BSMOMutationPredictiveDoes Not SupportSensitivity/ResponseCancerVismodegibHainsworth et al., 2018
BERBB2MutationPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaPertuzumab,TrastuzumabHainsworth et al., 2018
BERBB2AmplificationPredictiveSupportsSensitivity/ResponseBiliary Tract CancerPertuzumab,TrastuzumabHainsworth et al., 2018
BERBB2AmplificationPredictiveSupportsSensitivity/ResponseSalivary Gland CarcinomaPertuzumab,TrastuzumabHainsworth et al., 2018
BERBB2AmplificationPredictiveSupportsSensitivity/ResponsePancreatic CancerPertuzumab,TrastuzumabHainsworth et al., 2018
BERBB2AmplificationPredictiveDoes Not SupportSensitivity/ResponseUterine CancerTrastuzumab,PertuzumabHainsworth et al., 2018
CIDH1R132HPredictiveDoes Not SupportSensitivity/ResponsePancreatic Ductal AdenocarcinomaIvosidenibBrody et al., 2018
CEGFRT790MPredictiveDoes Not SupportSensitivity/ResponsePancreatic AdenocarcinomaOsimertinibCecchini et al., 2017
Cv::ALKFusionPredictiveSupportsSensitivity/ResponseVagina SarcomaCrizotinibForde et al., 2016
Cv::ALKFusionPredictiveSupportsSensitivity/ResponseEpithelioid Inflammatory Myofibroblastic SarcomaCrizotinibKimbara et al., 2014
CCTNNB1S45FPredictiveDoes Not SupportSensitivity/ResponseDesmoid TumorMeloxicamHamada et al., 2014
CVHLG144E (c.431G>A)PredisposingSupportsUncertain SignificanceAdrenal Gland Pheochromocytomavan der Harst et al., 1998
CVHLSplice Region (c.463+8C>T)PredisposingSupportsUncertain SignificanceAdrenal Gland Pheochromocytomavan der Harst et al., 1998
CVHLG104A (c.311G>C)PredisposingN/AVon Hippel-Lindau DiseaseOlschwang et al., 1998
CVHLF91L (c.273C>G)PredisposingN/AVon Hippel-Lindau DiseaseOlschwang et al., 1998
CVHLL184P (c.551T>C)DiagnosticSupportsPositiveClear Cell Renal Cell CarcinomaGallou et al., 2001
CERBB2OverexpressionPredictiveSupportsSensitivity/ResponseSalivary Gland CancerTrastuzumab,PaclitaxelFirwana et al., 2012
CEGFRG719APredictiveDoes Not SupportSensitivity/ResponseLung Non-small Cell CarcinomaErlotinib,GefitinibLocatelli-Sanchez et al., 2013
Page 82 of 96
PreviousNext